Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MELY will be well over .01 in 2 weeks. Mark this post. https://www.facebook.com/pages/Millionaire-Sailor/357745587698130
MONARCH BAY, CA, Apr 03, 2014 (Marketwired via COMTEX) -- Microelectronics Technology Corporation (OTCBB: MELY) (OTCQB: MELY), is pleased to announce the Company has completed negotiations for the acquisition of an established digital mining company and its digital mining assets. The acquisition is now subject to final formal documentation to be completed by April 18, 2014.
The acquisition includes the existing operational digital mining servers and support software. The Digital Currency Mining servers are currently being transitioned to the Dynamo Server co-location facilities with the transition expected to be completed by month's end. This transition will allow for peak efficiency utilizing the state of the art server facility and seamless expansion capability Dynamo servers can provide.
Bitcoin Mining: BTC
Upon the completion of the Digital Mining Server installation at the Dynamo Server co-location facilities, the company will begin to offer fractional Bitcoin Digital Currency Mining server rentals to interested third parties for an annual fee based upon the hash rate available for partitioning.
It is anticipated that the partitions will be available for lease in minimum 20 Gh/s hash rates with any multiple of 20 Gh/s available.
"The acquisition of a Bitcoin Digital Currency Mining Corporation is an exciting development for Microelectronics Technology Co for several reasons," states company president Brett Everett. "With this acquisition the company is acquiring a new customer for the Dynamo Server division creating a vertical with significant growth potential at the same time entering into the dynamic Bitcoin arena with a business model that creates opportunity for entry level investors to participate in Bitcoin mining with limited financial exposure." The company expects to announce the completion of formal documentation by April 18, 2014.
The Dynamo Servers platform was built from the ground-up to accommodate the needs of modern dedicated server customers, with features that are unique to the market. A simplified pricing model was applied to an expansive configuration system, allowing for predictable pricing without the customization limitations or penalties that are common among providers. An API was built to allow for integration with custom software and 3rd-party services. Social features were added to enable a dialogue among customers and a level of transparency unheard of in the industry. As long-time dedicated server customers, the people behind Dynamo Servers built a platform that they would want to use themselves.
Big breakout after .0009
TLNUF is getting super thin! it's ready for a huge run.
Just a couple days away before the deal is complete. No Dilution and Big $$ Acquisition to be completed 3/31. Also don't forget 30,000 square foot medical marijuana cultivation facility, whereby Primco will own 100% of the building, land and equipment and has granted CanMED a 10-year management contract for the operation of the Joint Venture.
#LONG AND STRONG PMCM
Easily .05+ No Dilution and Big $$ Acquisition to be completed 3/31. Also don't forget 30,000 square foot medical marijuana cultivation facility, whereby Primco will own 100% of the building, land and equipment and has granted CanMED a 10-year management contract for the operation of the Joint Venture.
#GO PMCM
No, the float is 1 bill
Multi Bagger No Dilution and Big $$ Acquisition to be completed 3/31. Also don't forget 30,000 square foot medical marijuana cultivation facility, whereby Primco will own 100% of the building, land and equipment and has granted CanMED a 10-year management contract for the operation of the Joint Venture.
#GO PMCM
Easily .05+ No Dilution and Big $$ Acquisition to be completed 3/31. Also don't forget 30,000 square foot medical marijuana cultivation facility, whereby Primco will own 100% of the building, land and equipment and has granted CanMED a 10-year management contract for the operation of the Joint Venture.
#GO PMCM
So much upside http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9870861 Suzie Q's acquisition will be completed in 5 days! big revs $$ with already 1,500 patients.
#GO PMCM
You're missing out... FFFC is just cooling down during lunch hours. One of the cheapest MMJ plays around at the moment.
yup, FFFC is about to take off. Especially with this news.
WEST PALM BEACH, FL, Mar 25, 2014 (Marketwired via COMTEX) -- FastFunds Financial Corporation ("FastFunds" or the "Company") (OTCQB: FFFC) wholly-owned subsidiary, Cannabis Angel, Inc., a company involved in providing financing alternatives, corporate finance and general management consulting services to early-stage cannabis companies and projects, through its 49% owned subsidiary Cannabis Merchant Financial Solutions, Inc. ("CMFS") has reached an agreement to offer smart debit cards specifically targeted for the cannabis industry.
This smart card technology will allow retail store owners to load a custom card with a cash balance. By loading the smart card, the store owner can eventually reduce the amount of cash carried into the store by the retailer's customers.
In addition, the smart card has multifaceted storage capabilities. The card can be used as a customer retention and incentive card. This feature will give the store owner a mechanism to incent the retailer's customers to come back to their store for additional products. Specifically, the smart card will add the following benefits:
-- Unlimited cash load capability on the card
-- Personalized card with the businesses name and logo
-- Reduced cash carried into the store by the retailer's customers
-- Guaranteed return foot traffic to the merchant's establishment
-- Technology advantage over the retailer's competitors
-- Multiple incentive and rewards capabilities with the card
-- State of the art customer retention program
The smart card will continue beta testing in Colorado and several other state retail locations throughout the months of March and April. It is the Company's intention to grow this smart card technology nationwide to assist with the challenge of surplus cash retained in cannabis locations.
The Company looks forward to providing regular updates in the coming weeks ahead.
About Cannabis Merchant Financial Solutions, Inc.
CMFS, located in Centennial, Colorado and Chaska, Minnesota, is dedicated to providing creative financial solutions for the cannabis industry. For more information, please visit the website:
www.cannabismerchantfinancialsolutions.com
Strong support building and ASK getting slapped hard.
We got a LOW FLOAT runner ahead!
Heavy buys coming in getting ready for power hour.
#GO UTRM
UTRM is thin all the way past .01 and this is way undervalued considering United Treatment Centers Completes Retirement of Three Billion Shares of Outstanding Stock
Big revenue will be posted next Q with bunch of ad's they already run. This is the only MMJ news center which means major $$.
I agree, this should easily be valued at a .01 with the patents they already hold and future game changing patents.
MCT-485 has demonstrated in in vitro models the ability to kill transformed liver cancer cells while not harming normal, non-transformed liver cells. "MCT-485 addresses the need to directly target liver cancer cells and not normal liver cells"
Yup, Big money coming in. $200k+ dollars buy came in right at closing.
Game Changing Technology.
MultiCell Technologies Files U.S. and International Patent Applications for the Treatment of Liver Cancer
WOONSOCKET, R.I., March 20, 2014 /PRNewswire via COMTEX/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) has filed additional U.S. and international patent applications covering MCT-485 and its composition of matter, biological targets, mechanism of action, and methods and formulations for therapeutic use.
MCT-485 is a very small noncoding double stranded RNA (dsRNA) molecule which has demonstrated a unique cytotoxic, oncolytic, and immune stimulating activity in in vitro models of hepatocellular carcinoma. MCT-485 is thought to target cancer by delivering a cytotoxic and oncolytic effect to only those cells having the highest tumor initiating capability that are part of the cancerous process such as cancer stem cells and tumor initiating cells. MCT-485 appears to have no effect on cells not directly involved in the process of relapse, progression and metastasis of cancer.
MCT-485 has demonstrated in in vitro models the ability to kill transformed liver cancer cells while not harming normal, non-transformed liver cells. "MCT-485 addresses the need to directly target liver cancer cells and not normal liver cells", said W. Gerald Newmin, Chairman and Chief Executive Officer. MCT-485 is currently being evaluated in animal models of hepatocellular carcinoma. MultiCell also plans to study MCT-485 in relevant in vitro and animal models for other major cancers.
In contrast to other species of RNAs including siRNAs, MCT-485 appears to induce cancer cell death through a biological process called pyroptosis; a caspase 1-dependent self-destruction cell death that involves pro-inflammatory cytokine production. Typically, pyroptosis is triggered by various pathological stimuli. MCT-485 is thought to suppress or modify the amount of mRNA being expressed by various genes linked to the metabolism, proliferation and viability of cancer cells thereby inducing a state of cellular stress within the cancer cell. MCT-485 appears to exert a preferential biological activity on transformed liver cancer cells while showing no effect on normal, non-transformed liver cells.
Treatment of hepatocellular carcinoma, the most common form of primary liver cancer, represents a major unmet medical need. Hepatocellular carcinoma is a leading cause of cancer death worldwide, and is the fourth most common cancer in the world. Over 1 million cases of hepatocellular carcinoma are reported annually worldwide. Current approaches for treatment of hepatocellular carcinoma are of limited efficacy. According to the U.S. National Cancer Institute (NCI), only 16% of patients diagnosed with primary liver cancer survive longer than 5 years. MCT-485, possessing oncolytic and immune activating properties, could be superior to currently marketed therapies by providing highly targeted killing of liver cancer cells coupled with a more robust activation of immunity and a global and longer lasting anti-tumor effect. Additionally, due to its unique mechanism of action, MCT-485 could also prove effective in killing other types of cancers.
About MCT-485
MultiCell Technologies' MCT-485 is a very small noncoding double stranded RNA (dsRNA) possessing a unique mechanism of action, and is the first of a family of prospective cancer therapeutics. MultiCell owns rights to several issued U.S. and foreign patents and patent applications related to MCT-485.
Nice got my fill. Lock and loaded.
MCT-485 has demonstrated in in vitro models the ability to kill transformed liver cancer cells while not harming normal, non-transformed liver cells. "MCT-485 addresses the need to directly target liver cancer cells and not normal liver cells"
Due to its unique mechanism of action, MCT-485 could also prove effective in killing other types of cancers
.0004's is about to be up
Yah i'll probably do the same and buy at 1's
SUTI creating alot of bag holders...
you got that right! Recap on news.
MultiCell Technologies Files U.S. and International Patent Applications for the Treatment of Liver Cancer
WOONSOCKET, R.I., March 20, 2014 /PRNewswire via COMTEX/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) has filed additional U.S. and international patent applications covering MCT-485 and its composition of matter, biological targets, mechanism of action, and methods and formulations for therapeutic use.
MCT-485 is a very small noncoding double stranded RNA (dsRNA) molecule which has demonstrated a unique cytotoxic, oncolytic, and immune stimulating activity in in vitro models of hepatocellular carcinoma. MCT-485 is thought to target cancer by delivering a cytotoxic and oncolytic effect to only those cells having the highest tumor initiating capability that are part of the cancerous process such as cancer stem cells and tumor initiating cells. MCT-485 appears to have no effect on cells not directly involved in the process of relapse, progression and metastasis of cancer.
MCT-485 has demonstrated in in vitro models the ability to kill transformed liver cancer cells while not harming normal, non-transformed liver cells. "MCT-485 addresses the need to directly target liver cancer cells and not normal liver cells", said W. Gerald Newmin, Chairman and Chief Executive Officer. MCT-485 is currently being evaluated in animal models of hepatocellular carcinoma. MultiCell also plans to study MCT-485 in relevant in vitro and animal models for other major cancers.
In contrast to other species of RNAs including siRNAs, MCT-485 appears to induce cancer cell death through a biological process called pyroptosis; a caspase 1-dependent self-destruction cell death that involves pro-inflammatory cytokine production. Typically, pyroptosis is triggered by various pathological stimuli. MCT-485 is thought to suppress or modify the amount of mRNA being expressed by various genes linked to the metabolism, proliferation and viability of cancer cells thereby inducing a state of cellular stress within the cancer cell. MCT-485 appears to exert a preferential biological activity on transformed liver cancer cells while showing no effect on normal, non-transformed liver cells.
Treatment of hepatocellular carcinoma, the most common form of primary liver cancer, represents a major unmet medical need. Hepatocellular carcinoma is a leading cause of cancer death worldwide, and is the fourth most common cancer in the world. Over 1 million cases of hepatocellular carcinoma are reported annually worldwide. Current approaches for treatment of hepatocellular carcinoma are of limited efficacy. According to the U.S. National Cancer Institute (NCI), only 16% of patients diagnosed with primary liver cancer survive longer than 5 years. MCT-485, possessing oncolytic and immune activating properties, could be superior to currently marketed therapies by providing highly targeted killing of liver cancer cells coupled with a more robust activation of immunity and a global and longer lasting anti-tumor effect. Additionally, due to its unique mechanism of action, MCT-485 could also prove effective in killing other types of cancers.
About MCT-485
MultiCell Technologies' MCT-485 is a very small noncoding double stranded RNA (dsRNA) possessing a unique mechanism of action, and is the first of a family of prospective cancer therapeutics. MultiCell owns rights to several issued U.S. and foreign patents and patent applications related to MCT-485.
Multi Million Dollar/Game Changing Patent! MCT-485 has demonstrated in in vitro models the ability to kill transformed liver cancer cells while not harming normal, non-transformed liver cells. "MCT-485 addresses the need to directly target liver cancer cells and not normal liver cells"
Get in now before we hit pennies.
Multi Million Dollar/Game Changing Patent! MCT-485 has demonstrated in in vitro models the ability to kill transformed liver cancer cells while not harming normal, non-transformed liver cells. "MCT-485 addresses the need to directly target liver cancer cells and not normal liver cells"
Yessir, MCET consolidating perfectly for the next leg up after lunch.
Same took a starter at .0021 also. Easy 5 bagger with this multi-million dollar patent. Super undervalued for a biopharmaceutical company.
#GO MCET
you got that right... i'm trying to load the boat at .0008
Yup there will be alot of buying pressure coming in tomorrow... i'm looking to pick up 15 mill tomorrow if it opens under .0015-.0016 range.
weak hands getting shaken out here
#GO SUTI
Next leg up is coming.
Yessir, Heavy accumulation into smart hands today.
#GO HIMR
easily a 10 bagger... did you see how thin the .0004 was getting at end of the day?
30 mill at .0003
My bid is not filling! Crazy HIMR news North Cal is conducting a market research study on Hemp, with a goal of launching a pilot project to cultivate organic hemp in aquaponic systems applying new aquaculture and biodynamic farming practices. Hollund's interest in North Cal's project revolves around possibilities being explored by the Company to enhance the sustainability and profitability of underwater timber projects -- such as the Bayano project in Panama -- as well as to diversify into new markets.
It's cause NT#K is a great investment :D been in it for well over a year already holding many shares. Glad to see you here at ITNS. Great play ahead.
patented mobile payment app that will facilitate point of purchase transactions for medical marijuana, gambling, and general retail sales. It's like a paypal but they're mainly aimed towards MMJ medical payments but works for everything else too. Big $$ patent.
Yessir, It looked like mostly big outside money too at the end of the day. Not little IHUB money. If you missed the news.. https://www.facebook.com/pages/Millionaire-Sailor/357745587698130
#GO ITNS
Easily that price... that patent alone will rake in multi-million dollar revenues for ITNS